Market PotentialThe company is focusing efforts on the lucrative opportunity in 1L non-classical/PACC EGFR mutations, which presents a potentially larger market.
Partnership And CollaborationBlack Diamond announced a global licensing agreement with Servier to develop BDTX-4933, extending the company's cash runway.
Regulatory ProgressManagement plans to use the emerging 1L data to meet with regulators regarding a registrational path forward in 1L, leading to a regulatory update for investors.